Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese*1, A. Hart2, A. Dignass3, G. Fiorino1, E. Louis4, G. D'Haens5, I. Dotan6,7, G. Rogler8, K. Paridaens9, L. Peyrin-Biroulet10

1IBD Center Humanitas Clinical and Research Centre, Rozzano, Milan, Italy, 2St Mark's Hospital, Harrow, UK, 3Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany, 4CHU de Liège, Liège, Belgium, 5Academic Medical Centre, Amsterdam, The Netherlands, 6Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, 7The Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 8Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 9Global Medical Affairs Gastroenterology, Ferring Pharmaceuticals Center S.A, Saint-Prex, Switzerland, 10Department of Gastroenterology and Inserm u954, Lorraine University, Nancy, France

P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Sebastian*1,2, S. Myers1, N. Syed1, K. Argyriou3, G. Martin4, L. Los5, J. Fiske6, R. Ranjan7, B. Cooper8, N. Patel9, V. Goodoory10, F. Shaikh10, H. L. Ching11, N. Jayasooriya12, J. Brooks13, A. Dhar7, A. H. Shenoy8, J. Limdy6, J. Butterworth5, P. B. Allen4, S. Samuel3, G. Moran3, R. Shenderey10, G. Parkes12, A. Lobo11, S. Subramanian9, T. Raine14

1IBD Unit, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK, 2Hull York Medical School, University of Hull and York, Hull, UK, 3Nottingham University Hospitals NHS Trust, Nottingham, UK, 4South Eastern Trust, Belfast, UK, 5Royal Shrewsbury Hospitals NHS Trust, Shrewsbury, UK, 6Pennine Acute Hospitals NHS Trust, Manchester, UK, 7County Durham and Darlington NHS Foundation Trust, Durham, UK, 8Colchester Hospital University Foundation Trust, Colchester, UK, 9Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK, 10Airedale NHS Foundation Trust, Airedale, UK, 11Sheffield Teaching Hospitals NHS Trust, Sheffield, UK, 12Royal London Hospital, Barts Health NHS Trust, London, UK, 13Addenbrookes Hospital, University of Cambridge, Cambridge, UK, 14Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Escher*1, B. Gold2, J. Izanec3, C. Busse4, Y. Wang5, S. Cucchiara6

1Erasmus MC-Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands, 2GI Care for Kids and Emory University Hospital, Atlanta, USA, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Pharmaceuticals, Horsham, USA, 5Janssen Research and Development, LLC, Spring House, USA, 6Sapienza University of Rome, Rome, Italy

P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Ochsenkühn1, C. Tillack2, F. Schnitzler3, D. Szokodi2, S. Janelidze2

1Isarklinikum München, Gastroenterology, Munich, Germany, 2IBD center Munich, Munich, Germany, 3Gastroklinik Pasing, Munich, Germany

P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods

ECCO '19 Copenhagen

Year: 2019
Authors:

M. McDonnell*1, R. Harris1, T. Mills1, L. Downey1, S. Dharmasiri1, R. Felwick1, F. Borca2, H. Phan2, F. Cummings1,3, M. Gwiggner1

1University Hospital Southampton, Gastroenterology, Southampton, UK, 2University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK, 3University of Southampton, Faculty of Medicine, Southampton, UK

P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, S. Verstockt3, J. Dehairs4, V. Ballet1, H. Blevi2, W-J. Wollants2, C. Breynaert5, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium

P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Simões*1, S. Fernandes1, S. Bernardo1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Tato Marinho1

1Hospital de Santa Maria, Gastroenterology, Lisbon, Portugal

P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Ishikawa*1, M. Takahashi1, K. Okahara1, S. Ito1, K. Haga1, T. Shibuya1, T. Osada2, A. Nagahara1

1Juntendo University, Gastroenterology, Tokyo, Japan, 2Juntendo Urayasu Hospital, Gastroenterology, Urayasu, Japan

P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme

ECCO '19 Copenhagen

Year: 2019
Authors:

F. A. Farraye1, T. Qazi1, P. G. Kotze*2, G. T. Moore3,4, C. Kayhan5, R. Mundayat5, E. Maller5, C. Su5, A. Soonasra5

1Boston Medical Center, Section of Gastroenterology, Boston University School of Medicine, Boston, MA, USA, 2Cajuru University Hospital, Pontifical Catholic University of Paraná (PUCPR), IBD Outpatient Clinics, Colorectal Surgery Unit, Curitiba, Brazil, 3Monash Health, Department of Gastroenterology, Melbourne, VIC, Australia, 4Monash University, School of Clinical Sciences at Monash Health, Melbourne, VIC, Australia, 5Pfizer Inc., Collegeville, PA, USA

P389: Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Steenstraten1, K. Sebib Korkmaz1, P. Trivedi3,4,5,6, A. Inderson1, B. van Hoek1, M. Rodriguez Girondo7, J. Maljaars*1

1LUMC, Gastroenterology-Hepatology, Leiden, The Netherlands, 3National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK, 4University Hospitals Birmingham, Birmingham, UK, 5University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, UK, 6University of Birmingham, Institute of Applied Health Research, Birmingham, UK, 7LUMC, Department of Biomedical Data Sciences, Leiden, The Netherlands

P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Colombo*1, A. Frontali2, L. Conti1, C. Baldi1, S. Ardizzone3, G. Maconi3, F. Corsi4, D. Foschi1, G. M. Sampietro1

1Luigi Sacco University Hospital, General Surgery, Milano, Italy, 2Hôpiteau de Paris (AP-HP), Beaujon Hospital, University Denis Diderot, Department of Colorectal Surgery, Pôle des Maladies de l'Appareil Digestif (PMAD),, Paris, France, 3Luigi Sacco University Hospital, Gastroenterology, Milano, Italy, 4ICS Maugeri, General Surgery Department, Pavia, Italy

P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Valdes Delgado1, M. Guerra Veloz*1, M. Belvis Jimenez1, B. Maldonado Pérez1, L. Castro Laria1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, T. Ortiz3, A. Caunedo Álvarez1, A. Vilches Arenas4, A. Saez Diaz5, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Seville, Spain, 2Virgen Macarena Hospital, Pharmacy Unit, Seville, Spain, 3University of Seville, Seville, Spain, 4Virgen Macarena Hospital, Preventive Medicine and Public Health, Seville, Spain, 5Virgen Macarena Hospital, Statistics, Seville, Spain

P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Soufleris*1, K. Fasoulas1, N. Kafalis1, G. Lazaraki1, D. Tzilves1

1Theagenion CHT, Gastroenterology Department, Thessaloniki, Greece

P393: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Sider1, S. Chadokufa1, R. Buckingham1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1

1Great Ormond Street Hospital, Gastroenterology, London, UK

P394: Contribution of the CDEIS in the new therapeutic approach of Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Sabbek*1, N. Elleuch2, A. Ben Slama2, E. Hammami2, H. Jaziri2, A. Braham2, S. Ajmi2, M. Ksiaa2, A. Jmaa2

1Sahloul Sousse, Gastroenterology, Sousse, Tunisia, 2Sahloul Sousse, Sousse, Tunisia

P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

Y. Nagata*1,2, M. Esaki3, Y. Fuyuno2, Y. Okamoto2, S. Fujioka2, A. Hirano2, J. Umeno2, T. Torisu2, T. Moriyama2, S. Nakamura1, T. Kitazono2

1Steel Memorial Yawata Hospital, Department of Gastroenterology, Fukuoka, Japan, 2Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 3Saga University Hospital, Department of Endoscopy, Saga, Japan

P396: Monitoring adalimumab compliance using smart sharp bin technology

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Hazel*1, C. Smyth1, O. Kelly1, R. J. Farrell1

1Connolly Hospital, Blanchardstown, Department of Gastroenterology, Dublin, Ireland

P397: Autologous stem cell transplantation in refractory Crohn's disease: evaluation of a modified mobilisation regimen and analyses of the cost-effectiveness

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Mahmmod*1, S. Mahmmod2, M. Severs2, H. Koene3, F. van Wijk4, B. Oldenburg2, H. Fidder2

1Sint Antonius Teaching Hospital, Gastroenterology, Nieuwegein, The Netherlands, 2University Medical Center Utrecht, Gastroenterology, Utrecht, The Netherlands, 3Sint Antonius Teaching Hospital, Hematology, Nieuwegein, The Netherlands, 4University Medical Center Utrecht, Pediatrics, Laboratory of Translational Immunology, Utrecht, The Netherlands

P398: Leptin controls immune cell composition and activity in acquired generalised lipodystrophy with combined Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. F. Ziegler*1, C. Böttcher2, H. Wu1, R. Glauben1, B. Siegmund1, C. Weidinger1,3

1Charité - Universitätsmedizin Berlin, Department of Gastroenterology, Rheumatology and Infectious Disease, Campus Benjamin Franklin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, Laboratory of Molecular Psychiatry and Department of Neuropsychiatry, DZNE Berlin, Berlin, Germany, 3Berlin Institute of Health, Berlin, Germany

P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Steen*1, M. McCormack2, C. McShane1, M. Healy2, V. Crowley2, U. Kennedy1, O. Hayes1, C. Dunne1, K. Hartery1, S. McKiernan1, F. MacCarthy1, D. Kevans1

1St. James Hospital, Gastroenterology, Dublin, Ireland, 2St. James Hospital, Biochemistry, Dublin, Ireland